The world nowadays is succumbing to the widespread prevalence of colorectal cancer.
Factors such as changing lifestyle and ignorance towards health related issues have led to the growing incidence of this disease.
Much of the research in the field of colorectal cancer is directed towards developing a robust therapeutics drug pipeline in order to restrict the colorectal cancer cells from growing further, in that way, prolonging the life of the patient.

Browse the full Global Colorectal Cancer Therapeutics Market Report : http://www.mrrse.com/colorectal-cancer-therapeutics

The colorectal cancer therapeutics market is spread across eight major regional markets such as the U.S., the U.K., Germany, France, Italy, Japan, Canada, and Spain.
These markets collectively are expected to rise at a CAGR of 1.8% to reach US$9.4 billion by 2020. Regionally, the colorectal cancer therapeutics market in the U.S. dominated the overall market in 2013, holding a share of 44.1% in the overall market.
Japan stood second with 14.7% and Germany occupied third position with 11.9% share.
The colorectal cancer therapeutics market in Spain accounted for the lowest share in the market with just 4.1%. In the long run, the market in Japan is expected to register the fastest growth at a CAGR of 5% during the period from 2014 to 2020.
As the colorectal cancer therapeutics market is exhibiting a moderate but steady growth, let us take a look on the impact of prevalent drugs on the market:
The expiration of the patents of Erbitux and Avastin, which are major drugs widely used in the treatment of colorectal cancer is impending.
The uptake of lower-priced biosimilar versions of cetuximab and bevacizumab is expected to rise, limiting the already-moderate growth of the market.
The roll-out of generic versions of capecitabine is also announced and is expected to hamper the market growth to a great extent.
However, the launches of premium-priced developing therapies for the treatment of colorectal cancer are expected to balance the market.
Stivarga (regorafenib tab) is expected to drive the colorectal cancer therapeutics market significantly as its expected line extension is in the first-line metastatic setting, which will be used as the maintenance treatment for patients, who have resected liver metastases.
Another drug, Lonsurf (TAS-102), approved in Japan for the treatment of advanced metastatic colorectal cancer is gaining immense popularity among patients as it is more tolerable compared to Stivarga.
Xilonix and Panitumumab are expecting their approval, after which they are projected to trigger additional market growth.
Browse the full Press Release of Colorectal Cancer Therapeutics Market : http://www.mrrse.com/colorectal-cancer-therapeutics-market-report
The future of colorectal cancer therapeutics market is showing signs of healthy growth facilitated by potential drugs under various phases of clinical development and around 400 active pipeline molecules.
Pfizer Inc., Ingelheim, Bayer Healthcare Pharmaceuticals, Eli Lilly and Co., and Taiho Pharmaceutical are the major participants operating in the colorectal cancer therapeutics market.

Send An Enquiry: http://www.mrrse.com/enquiry/114

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Colorectal Cancer
2.2 Symptoms
2.3 Epidemiology
2.4 Pathophysiology
2.4.1 Histology
2.4.2 Genetic Basis
2.4.3 Etiology of Colorectal Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Fecal Occult Blood Test
2.5.3 Flexible Sigmoidoscopy
2.5.4 Colonoscopy
2.5.5 Virtual Colonoscopy
2.5.6 Double Contrast Barium Enema
2.6 Prognosis and Disease Staging
2.7 Treatment Options
2.7.1 Surgery and Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Targeted Therapies
2.7.4 Resistance to Pharmacological Therapies
2.7.5 Treatment Guidelines
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Key Marketed Products
3.1.1 Immunotherapies
3.1.2 Targeted Therapies
3.1.3 Hyperthermic Intraperitoneal Chemotherapy
3.2 Heat Map for Marketed Products

4 Pipeline Analysis
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.5 Failure Rate
4.6 Clinical Trial Size
4.7 Duration
4.8 Promising Drug Candidates in Pipeline
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical
4.8.2 Cyramza – ramucirumab – Eli Lilly and Company
4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical
4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals
4.8.5 MelCancerVac – DanDrit Biotech
4.8.6 Xilonix – XBiotech
4.8.7 Nintedanib – Boehringer Ingelheim

5 Market Forecast to 2020
5.1 Global Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 North America
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Top Five European Markets
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020
5.5.1 Drivers
5.5.2 Barriers

6 Deals and Strategic Consolidations
6.1 Licensing Agreements
6.1.1 Major Licensing Deals
6.2 Co-development Agreements
6.2.1 Major Co-development Agreements

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.2 Market Forecasts to 2020
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer


State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-618-1030
Email: [email protected]
Website: http://www.mrrse.com/